1. ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY. (12th June 2019) Authors: Witzig, T.E.; Maddocks, K.; de Vos, S.; Lyons, R.; Edenfield, W.; Sharman, J.; Vose, J.; Yimer, H.; Wei, H.; Chan, E.; Patel, P.; Di Simone, C.; Gandhi, M.; Vaughn, J.; Kolibaba, K.; Cheson, B.; Samaniego, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. (June 2017) Authors: Fowler, N.; Gopal, A.K.; Schuster, S.J.; Trotman, J.; Hess, G.; Hou, J.; Yacoub, A.; Lill, M.; Martin, P.; Vitolo, U.; Spencer, A.; Radford, J.; Jurczak, W.; Morton, J.; Osmanov, D.; Caballero, D.; Deshpande, S.; Vermeulen, J.; Damle, R.; Schaffer, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1130: ACALABRUTINIB IN TREATMENT-NAIVE OR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: 5-YEAR FOLLOW-UP OF A PHASE 2, SINGLE-ARM STUDY. (23rd June 2022) Authors: Owen, R.; McCarthy, H.; Rule, S.; D'Sa, S.; Thomas, S.; Tournilhac, O.; Forconi, F.; José Kersten, M.; Luigi Zinzani, P.; Iyengar, S.; Kothari, J.; Minnema, M.; Kastritis, E.; Cheson, B.; Walter, H.; Greewald, D.; Calvo, R.; Wun, C.-C.; Furman, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1020 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗